Indica Labs vs Proscia
Both are FDA cleared platforms for primary diagnosis, so the question is not who is authorized but what shape of platform you want. If maximum scanner freedom and the broadest cleared scope matter most, start with Indica Labs. If you want a platform whose AI is more woven in and that carries both US and EU clearance in a single edition, start with Proscia. Indica leads on interoperability, cleared across two scanner makers with DICOM portability and outside algorithm hosting, and its clearance covers surgical pathology generally. Proscia scores its AI higher because the platform actively recommends stain panels and scores PD-L1, HER2, and Ki-67 in the viewer, and it holds the strongest oversight posture here, arguing publicly for expert verification rather than replacement.
- Widest scanner and interoperability freedom: cleared across Hamamatsu and Leica scanners, DICOM portable, and able to host outside algorithms, the only A on interoperability among these platforms.
- Broadest cleared scope: primary diagnosis of surgical pathology slides generally rather than a single tumor type, versus Proscia's narrower laboratory and life sciences footprint.
- More documented compliance controls: states HIPAA compliance plainly and adds ISO 13485 and 21 CFR Part 11 electronic record controls, more than Proscia publishes on either front.
- AI is more native to the workspace: it recommends stain panels and ancillary tests from what it sees in tissue and scores PD-L1, HER2, and Ki-67 inline, earning a higher AI centrality grade than Indica.
- Clearance in both jurisdictions from one edition: FDA 510(k) and CE-IVDR for primary diagnosis, with a deployment that is not locked to a specific scanner.
- The strongest oversight posture in this group: built around expert verification, with the company arguing publicly that the opportunity is removing administrative burden rather than diagnostic expertise.
Side-by-Side
| Axis | I Indica Labs |
P Proscia |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Neither publishes pricing, and neither holds a SOC 2, HITRUST, or ISO 27001 attestation; Proscia's GxP readiness is a research quality framework, not information security. Indica's clearance is specific to named scanners, so hardware and software cost are a coupled decision, and it documents its own AI models thinly. Proscia holds whole slide images plus clinical metadata for both diagnostic laboratories and pharmaceutical research customers and does not publish where the boundary between those two data environments sits, nor its hosting or data residency terms. Both host outside algorithms that carry their own separate regulatory classifications, so platform clearance does not extend to the algorithms running on it, and each must be evaluated on its own.